Fig. 6
From: Establishment and validation of an immune infiltration predictive model for ovarian cancer
IPM predicts immunotherapeutic prognosis. A Kaplan-Meier analysis between the high-- and low- IPM group in the IMvigor210 cohort. B Risk score distribution for different anti-PD-L1 clinical responses in IMvigor210 cohort. C The relative proportion of clinical response to anti-PD-L1 immunotherapy in the high- and low- IPM group in IMvigor210 cohort (PD-progressive disease, SD-stable disease, PR-partial response, and CR-complete response). D ROC curves of TMB, risk score, and combination of TMB and risk score in IMvifor210 cohort. E Kaplan-Meier analysis between the high- and low- IPM group in GSE78220 cohort, (F) Risk score distribution for different anti-PD-1 clinical responses in GSE78220 cohort. G The relative proportion of clinical response to anti-PD-1 immunotherapy in the high- and low- IPM group in GSE78220 cohort. H ROC curves of the risk score in GSE78220 cohort. I)The risk score of each patient in GSE78220 cohort. J PD-L1 gene expression levels in the high- and low- IPM group. K The box plots of the estimated IC50 for the top 10 compounds in the high- and low- IPM group